Drawing for SATIO

USPTO serial 97512123

SATIO

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
PRIZANT, JAMES
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SATIO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joshua S. Jarvis, Esq.

Joshua S. Jarvis, Esq. FOLEY HOAG LLP155 SEAPORT BOULEVARDBOSTON, MA 02210United States

Goods and services

ClassDescriptionStatusFirst use
005Vaccines, namely, dermal patches featuring vaccines; pharmaceutical preparations for the prevention and treatment of infectious diseases and non-infectious diseases, namely, dermal patches featuring pharmaceutical preparations for the prevention and treatment of hepatic diseases, immune system diseases, renal diseases, metabolic diseases, endocrine diseases, thyroid diseases, diabetes, pancreatic diseases, cystic fibrosis, phenylketonuria, blood diseases, sickle cell disease, sickle cell anemia, galactosemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency; medical diagnostic reagents and assays for testing of body fluids, namely, dermal patches featuring medical diagnostics or assays for testing of body fluids; reagents for use in medical genetic testing, namely, dermal patches featuring reagents for use in medical genetic testingACTIVE—
010Medical diagnostic apparatus for testing DNA and RNA samples; medical diagnostic apparatus for testing for infectious diseases and non-infectious diseases, namely, hepatic diseases, immune system diseases, renal diseases, metabolic diseases, endocrine diseases, thyroid diseases, diabetes, pancreatic diseases, cystic fibrosis, phenylketonuria, blood diseases, sickle cell disease, sickle cell anemia, galactosemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency; genetic testing apparatus for medical purposes; dermal patches for delivery of pharmaceuticals and vaccines, sold empty; medical devices for obtaining body fluid samples; medical devices for testing body fluid samples; dermal patches for testing DNA and RNA samples; dermal patches for testing for infectious diseases and non-infectious diseases, namely, hepatic diseases, , immune system diseases, renal diseases, metabolic diseases, endocrine diseases, thyroid diseases, diabetes, pancreatic diseases, cystic fibrosis, phenylketonuria, blood diseases, sickle cell disease, sickle cell anemia, galactosemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency; dermal patches for testing for genetic testing; dermal patches for obtaining body fluid samples; dermal patches for testing body fluid samplesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 1, 2025MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 1, 2025ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 4, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 3, 2025EX3GSOU EXTENSION 3 GRANTED—
Apr 3, 2025EXT3SOU EXTENSION 3 FILED—
Apr 3, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 18, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 18, 2024EX2GSOU EXTENSION 2 GRANTED—
Sep 18, 2024EXT2SOU EXTENSION 2 FILED—
Sep 18, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 27, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 26, 2024EX1GSOU EXTENSION 1 GRANTED—
Apr 26, 2024EXT1SOU EXTENSION 1 FILED—
Apr 26, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 30, 2023NOACCORRECTED NOA E-MAILED—
Nov 29, 2023ICNANOTICE OF ALLOWANCE CORRECTION ENTERED—
Nov 9, 2023AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 31, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 24, 2023EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Sep 5, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 5, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 16, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 29, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 28, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 27, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 27, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 18, 2023GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 18, 2023GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 18, 2023CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 17, 2023GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 17, 2023GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 17, 2023CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 5, 2023DOCKASSIGNED TO EXAMINER—
Aug 10, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 23, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance